RNAi Technology Market Size, Share, Offering (Product and Services), Therapeutics (Oncology, Ocular Disorders, Respiratory Disorders, Hepatitis B and C, and Others), Delivery Method (Soaking, Nanoparticles, Viral Vectors, and Others), Application (Drug Discovery & Development, Functional Genomics, and Others), End-Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• SILENCE THERAPEUTICS
• Thermo Fisher Scientific Inc.
• Revvity Discovery Limited, Company
• OriGene Technologies, Inc.
• QIAGEN
•  Benitec Biopharma.
• Sirnaomics
• SiRNAgen Therapeutics Corporation
• Switch Therapeutics
• Altogen Biosystems
• Creative Biolabs
• City Therapeutics
• Mirimus

Recent News:

• City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announced that it has entered into a strategic collaboration with global eye health leader Bausch + Lomb in January 2025. Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
• Blackstone and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced the companies have entered into a broad strategic collaboration in April 2020, under which Blackstone will provide up to USD 2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.